- Home
- NMTC vs TVRD Comparison
NMTC vs TVRD Comparison
Compare NMTC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMTC | TVRD |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 37.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMTC | TVRD |
|---|---|---|
| Price | $0.91 | $4.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $2.23 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 392.8K | 149.5K |
| Earning Date | 02-11-2026 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,097,692.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 250.35 | N/A |
| 52 Week Low | $0.40 | $3.74 |
| 52 Week High | $1.39 | $43.65 |
Technical Indicators
Market Signals| Indicator | NMTC | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 49.71 |
| Support Level | $0.86 | $3.87 |
| Resistance Level | $0.93 | $4.75 |
| Average True Range (ATR) | 0.07 | 0.34 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 67.03 | 70.29 |
Price Performance
Historical ComparisonAbout NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.